Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levosimendan for ARDS prognosis and pulmonary hemodynamic optimization
ChiCTR1900024129Phase 4Not yet recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of levosimendan in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Shenzhen Second People's Hospital. Primary endpoints: APACHE II score and Cardiac function index. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
levosimendan
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on ChiCTR1900024129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024129.